Look-alike medications: a formula for possible morbidity and mortality in the long-term care facility

Grant Walliser1, Richard Grossberg, Michael D Reed

  • 1Hattie Larlham Center for Children with Disabilities, Hattie Larlham Research Institute, Mantua, Ohio, USA.

Insights

Medication errors cause significant patient harm and death. Differences in generic drug appearance can lead to dangerous dosing errors, especially in long-term care facilities.

Area of Science:

  • Pharmacology
  • Patient Safety
  • Health Policy

Background:

  • Medication errors are a major cause of patient morbidity and mortality, with millions of preventable adverse drug events occurring annually in the US.
  • Patients in long-term care facilities are at increased risk due to polypharmacy and cognitive impairment, complicating communication.
  • Financial constraints often lead to the use of generic medications, which may differ in appearance from brand-name drugs.

Observation:

  • Generic medications increasingly lack distinct visual characteristics, differing from brand-name counterparts.
  • Variations in appearance also exist between different generic manufacturers of the same drug.
  • These visual discrepancies can be a significant factor in medication errors.

Findings:

  • A case is presented where a patient in a long-term care facility received excessive doses of glipizide instead of baclofen due to medication mix-up.
  • This error highlights the potential for serious consequences arising from differences in drug appearance.

Implications:

  • The visual dissimilarity of generic drugs poses a substantial risk for medication errors, particularly in vulnerable patient populations.
  • Healthcare providers and facilities must implement strategies to mitigate risks associated with generic medication appearance.
  • Enhanced drug packaging and labeling standards may be necessary to improve patient safety and prevent future medication errors.

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...